Disease landscape

Pancreatic Cancer clinical trials

Get alerts when Pancreatic Cancer trials change

1,077 active trials 613 recruiting 68 Phase 3 558 sponsors 121 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-08-28

What changed in the last 30 days showing 45 of 121 changes on 20 trials

2026-08-01
Recruitment suspended
Recruitment suspended: PI Request
NCT07377526 TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer · M.D. Anderson Cancer Center · Phase 1/2
2026-08-25
Primary completion pushed: 2026-06 → 2027-06
Completion pushed: 2026-09 → 2027-09
NCT03257033 Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy… · RenovoRx · Phase 3
2026-08-27
Primary completion pushed: 2026-06 → 2026-12
NCT04157127 Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma · Diakonos Oncology Corporation · Phase 1
2026-08-28
Primary completion pushed: 2031-01-01 → 2033-04-01
Recruitment opened
Completion pushed: 2031-09-01 → 2034-09-01
NCT05314998 Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or… · John Neoptolemos · Phase 3
2026-08-22
Primary completion pushed: 2026-08-26 → 2028-08-26
Completion pushed: 2026-08-26 → 2028-08-26
NCT05554367 Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial · National Cancer Institute (NCI) · Phase 2
2026-07-31
Primary completion pushed: 2026-12 → 2028-01
Enrollment increased: 442 → 542 participants
Trial sites expanded: 79 → 82 locations
Completion pushed: 2027-12 → 2028-06
NCT04657068 A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors · Artios Pharma Ltd · Phase 1/2
2026-07-30
Primary completion pushed: 2026-08-11 → 2026-11-17
Completion moved earlier: 2027-09-30 → 2027-06-28
NCT06219941 AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 · AstraZeneca · Phase 2
2026-08-06
Primary completion pushed: 2026-05 → 2027-06
Primary endpoint(s) modified
Completion pushed: 2026-05 → 2027-06
Trial arms changed: 17 → 18
NCT04999761 AB122 Platform Study · Taiho Pharmaceutical Co., Ltd. · Phase 1
2026-08-05
Primary completion pushed: 2026-07 → 2027-09
Completion pushed: 2026-07 → 2027-09
Trial arms changed: 9 → 10
NCT06084481 Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With… · AbbVie · Phase 1
2026-08-01
Primary completion pushed: 2025-12 → 2027-03-31
Completion pushed: 2025-12 → 2027-03-31
NCT05759923 First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity… · Molecure S.A. · Phase 1
2026-08-21
Primary completion pushed: 2026-01-15 → 2027-01-15
Completion pushed: 2026-01-15 → 2027-02-15
NCT06453590 Treatment of Distal Malignant Biliary Obstruction by Uncovered, Partially Covered, or… · Region Stockholm
2026-08-27
Primary completion pushed: 2026-11-27 → 2027-11-27
Recruitment opened
Completion pushed: 2026-11-27 → 2027-11-27
NCT06893276 e-Health Psychosocial Stress and Symptom Management (ePSMI) for Pancreatic Cancer Patients · University of Miami
2026-08-20
Primary completion pushed: 2027-09-01 → 2028-09-01
Completion pushed: 2027-10-01 → 2028-12-01
NCT07175389 JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure · West China Hospital · Phase 1/2
2026-08-20
Primary completion pushed: 2026-07-15 → 2028-02-03
Completion pushed: 2026-11-24 → 2028-02-03
NCT03454035 Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors · UNC Lineberger Comprehensive Cancer Center · Phase 1
2026-08-26
Primary endpoint(s) modified
NCT07781852 Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and… · Lumina Pharmaceuticals Inc · Early Phase 1
2026-08-20
Primary completion pushed: 2026-06-18 → 2026-12-01
Completion pushed: 2026-06-18 → 2026-12-01
NCT07226154 Prediction of Neoadjuvant Chemotherapy Response in Pancreatic Cancer · City of Hope Medical Center
2026-07-30
Primary completion pushed: 2032-06 → 2032-10
Completion pushed: 2032-07 → 2032-11
NCT07528430 Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing… · University of Maryland, Baltimore
2026-08-05
Primary endpoint(s) modified
Trial completed
NCT04825288 XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer · XBiotech, Inc. · Phase 1/2
2026-08-01
Primary endpoint(s) modified
NCT07733427 Evaluating the Effectiveness of AIT in the Treatment of Pain Related to Pancreatic Cancer · Clinique Bizet
2026-08-01
Enrollment reduced: 117 → 31 participants
Enrollment closed, study ongoing
Trial sites reduced: 18 → 14 locations
NCT06921928 Study for AZD4360 in Participants With Advanced Solid Tumours · AstraZeneca · Phase 1/2

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-08-26 NCT07787156 Reach and Engagement of GENetic Education, Risk Assessment, and TEsting Feasibility Trial Brigham and Women's Hospital new
2026-08-24 NCT07781852 Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and… Lumina Pharmaceuticals Inc new Early Phase 1
2026-08-20 NCT07777211 A Phase I/IIa Study of GKL-006 Injection in Patients With Advanced Pancreatic Cancer Beijing Gene Key Life Technology Co., Ltd new Phase 1/2
2026-08-20 NCT07776353 Understanding New Cachexia Subtypes Through Observational Epidemiological Research Kaiser Permanente new
2026-08-19 NCT07772258 Wearable-Supported Prehabilitation and Rehabilitation for Patients Undergoing Surgery for… Manchester University NHS Foundation Trust new
2026-08-19 NCT07773363 Retlirafusp Alfa Plus Apatinib and Chemotherapy as Second-Line Treatment for Pancreatic… Tang-Du Hospital new Phase 2
2026-08-13 NCT07763561 EUS-DFI in Solid Pancreatic Lesions Julio Iglesias García new
2026-08-10 NCT07756281 First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic… Synnovation Therapeutics, Inc. new Phase 1
2026-08-07 NCT07752875 A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53… LG Chem new Phase 1/2
2026-07-31 NCT07738939 IKS04 Regimen in Advanced Solid Tumors That Express CA242 Iksuda Therapeutics Ltd. new Phase 1

Active trials by phase

Early Phase 1
38
Phase 1
161
Phase 1/2
146
Phase 2
230
Phase 2/3
20
Phase 3
48
Phase 4
12
Not charted: 422 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials top 25 of 1,077

NCT IDTitleSponsorStatusUpdated
Phase 4
NCT07262957 Preventing Postoperative Complications in Patients Undergoing High-risk… Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Recruiting 2025-12-22
NCT06099119 Efficacy of PERT for PEI in Unresectable Pancreatic Cancer. Hospital Clinico Universitario de Santiago Recruiting 2025-06-06
NCT05784311 Standard Versus Prolonged Antibiotic Prophylaxis After Pancreatoduodenectomy (SPARROW) Leiden University Medical Center Recruiting 2024-10-21
NCT06368063 The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic… Xi'an Jiaotong University Recruiting 2024-05-08
NCT05035147 Albumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic Cancer Tianjin Medical University Cancer Institute and Hospital Recruiting 2021-09-21
NCT07557394 A Prospective Non-randomized Controlled Interventional Study on the Effect of Shouhui… Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Not Yet Recruiting 2026-04-29
NCT05634720 Hepatic Artery Chemotherapy for Patients With Localized Pancreas Cancer Duke University Active, Not Recruiting 2026-01-26
NCT07302841 Tunlametinib + AG + Cetuximab β as First-Line Therapy for Advanced Pancreatic Cancer Tianjin Medical University Cancer Institute and Hospital Not Yet Recruiting 2025-12-24
NCT04025840 Perioperative Epidural Block and Dexamethasone in Pancreatic Cancer Surgery Peking University First Hospital Active, Not Recruiting 2025-07-31
NCT06779318 Maintenance Chemotherapy With S-1 vs. Observation After Adjuvant Therapy for Resected… The First Affiliated Hospital with Nanjing Medical University Not Yet Recruiting 2025-04-03
NCT06387368 Clinical Study of Huaier Granule in the Treatment of Unresectable Pancreatic Cancer Xi'an Jiaotong University Not Yet Recruiting 2024-04-29
NCT02775227 HYPAR Trial - Hydrocortisone vs. Pasireotide in Reducing Pancreatic Surgery Complications Helsinki University Central Hospital Active, Not Recruiting 2020-08-24
Phase 3
NCT05314998 Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or… John Neoptolemos Recruiting 2026-08-27
NCT07409272 A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either… Astellas Pharma Global Development, Inc. Recruiting 2026-08-27
NCT07491445 Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With… Revolution Medicines, Inc. Recruiting 2026-08-27
NCT06958328 Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer NRG Oncology Recruiting 2026-08-25
NCT07252232 Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal… Revolution Medicines, Inc. Recruiting 2026-08-25
NCT03257033 Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy… RenovoRx Recruiting 2026-08-24
NCT07562152 Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic… Immuneering Corporation Recruiting 2026-08-21
NCT07621718 Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of… Revolution Medicines, Inc. Recruiting 2026-08-21
NCT07262567 Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant… Genfleet Therapeutics (Shanghai) Inc. Recruiting 2026-08-14
NCT07232875 HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line… Jiangsu HengRui Medicine Co., Ltd. Recruiting 2026-07-15
NCT07436741 Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in… Tianjin Medical University Cancer Institute and Hospital Recruiting 2026-07-10
NCT07217717 Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal… SOFIE Recruiting 2026-06-30
NCT07632118 Radiotherapy With GX Regimen as Adjuvant Therapy for High-risk Patients Following… Tianjin Medical University Cancer Institute and Hospital Recruiting 2026-06-08
See all 1,077 active Pancreatic Cancer trials with filters →

Top sponsors by active trials in this area

National Cancer Institute (NCI) (30) · Fudan University (22) · Memorial Sloan Kettering Cancer Center (20) · M.D. Anderson Cancer Center (19) · Mayo Clinic (15) · Changhai Hospital (14) · Ruijin Hospital (14) · Tianjin Medical University Cancer Institute and Hospital (12) · Zhejiang University (12) · City of Hope Medical Center (11)

Get alerts when Pancreatic Cancer trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free